eIF4AIII Antibody (B-2): sc-365549

eIF4AIII Antibody (B-2) is a mouse monoclonal IgG2b kappa light chain antibody that detects eIF4AIII protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). anti-eIF4AIII antibody (B-2) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. eIF4AIII plays a crucial role in the regulation of gene expression and mRNA metabolism, as eIF4AIII is a key component of the exon junction complex (EJC), which is essential for mRNA surveillance and the enhancement of translation efficiency. The EJC assembles at exon-exon junctions following splicing, ensuring that only properly processed mRNAs are translated. Notably, eIF4AIII preferentially associates with spliced mRNA, distinguishing eIF4AIII from family members eIF4AI and eIF4AII, which are predominantly located in the cytoplasm. Nuclear localization of eIF4AIII enables regulation of mRNA export and stability, thereby influencing overall protein synthesis in response to cellular conditions. anti-eIF4AIII antibody (B-2) serves as an invaluable tool for researchers studying mechanisms of mRNA processing and translation regulation in various biological contexts.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

eIF4AIII Antibody (B-2) References:

1. Physical association of eukaryotic initiation factor 4G (eIF4G) with eIF4A strongly enhances binding of eIF4G to the internal ribosomal entry site of encephalomyocarditis virus and is required for internal initiation of translation.  |  Lomakin, IB., et al. 2000. Mol Cell Biol. 20: 6019-29. PMID: 10913184
2. Structural and functional similarities between the central eukaryotic initiation factor (eIF)4A-binding domain of mammalian eIF4G and the eIF4A-binding domain of yeast eIF4G.  |  Dominguez, D., et al. 2001. Biochem J. 355: 223-30. PMID: 11256967
3. Further characterization of the helicase activity of eIF4A. Substrate specificity.  |  Rogers, GW., et al. 2001. J Biol Chem. 276: 12598-608. PMID: 11278350
4. Eukaryotic initiation factors 4A (eIF4A) and 4G (eIF4G) mutually interact in a 1:1 ratio in vivo.  |  Li, W., et al. 2001. J Biol Chem. 276: 29111-5. PMID: 11408474
5. Modulation of the helicase activity of eIF4A by eIF4B, eIF4H, and eIF4F.  |  Rogers, GW., et al. 2001. J Biol Chem. 276: 30914-22. PMID: 11418588
6. The initiation factor eIF4A is involved in the response to lithium stress in Saccharomyces cerevisiae.  |  Montero-Lomeli, M., et al. 2002. J Biol Chem. 277: 21542-8. PMID: 11940596
7. DUG is a novel homologue of translation initiation factor 4G that binds eIF4A.  |  Göke, A., et al. 2002. Biochem Biophys Res Commun. 297: 78-82. PMID: 12220511
8. eIF4A3 is a novel component of the exon junction complex.  |  Chan, CC., et al. 2004. RNA. 10: 200-9. PMID: 14730019
9. Interaction between the NH2-terminal domain of eIF4A and the central domain of eIF4G modulates RNA-stimulated ATPase activity.  |  Korneeva, NL., et al. 2005. J Biol Chem. 280: 1872-81. PMID: 15528191
10. The EJC factor eIF4AIII modulates synaptic strength and neuronal protein expression.  |  Giorgi, C., et al. 2007. Cell. 130: 179-91. PMID: 17632064
11. CLIP-seq of eIF4AIII reveals transcriptome-wide mapping of the human exon junction complex.  |  Saulière, J., et al. 2012. Nat Struct Mol Biol. 19: 1124-31. PMID: 23085716
12. Crystal structure of the human eIF4AIII-CWC22 complex shows how a DEAD-box protein is inhibited by a MIF4G domain.  |  Buchwald, G., et al. 2013. Proc Natl Acad Sci U S A. 110: E4611-8. PMID: 24218557

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-eIF4AIII Antibody (B-2) has 9 citations in a variety of scientific publications.

Primary antibodies like Anti-eIF4AIII Antibody (B-2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

eIF4AIII Antibody (B-2) Specifications

Alternate Product Name: EIF4A3

Product Clone Name: B-2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids: 1-50

Epitope Target: eIF4AIII

Epitope Species: human

Product Reactivity/Detection: eIF4AIII

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 9 citations in various scientific publications

Available Conjugates/Forms for eIF4AIII Antibody (B-2): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin